Activated PI3K-Delta Syndrome (APDS)

Activated PI3K-delta Syndrome (APDS) is a rare, inherited immune system condition. It happens when a key signaling pathway in white blood cells (called the PI3K-delta pathway) is overactive. Because of this over-signaling, the immune system does not learn, balance, and fight germs properly. Many people with APDS get repeated infections of the ears, sinuses, and lungs. Swollen lymph nodes, a big spleen or liver, and bowel or airway problems can appear. Some patients develop autoimmune problems or certain blood-cell cancers. The root cause is a disease-causing change (mutation) in one of two genes—PIK3CD or PIK3R1—that control the PI3K-delta pathway in lymphocytes (T and B cells). Correct diagnosis needs a mix of clinical history, immune blood tests, and genetic testing. NCBIMedlinePlusJAC Online

Activated PI3K-delta syndrome (APDS) is a rare, inherited immune system disorder caused by a “gas-pedal-stuck” error in a signaling enzyme called PI3K-delta. Because that pathway runs hot, key white blood cells (T and B cells) don’t grow, mature, or communicate normally. People develop frequent ear, sinus, chest, and gut infections; large lymph nodes and spleen (lymphoproliferation); airway damage (bronchiectasis); and autoimmune problems like low platelets or anemia. APDS is most often due to variants in PIK3CD (APDS1) or PIK3R1 (APDS2). Diagnosis uses clinical clues plus genetic testing. Care centers on preventing infections (vaccines, immunoglobulin, antibiotics), controlling overactive immune signals (targeted or immune-modulating drugs), managing airway health, and—in selected severe cases—curative stem-cell transplant. NCBIPMCFrontiers

---

Another names

APDS is also called Activated Phosphoinositide 3-Kinase δ (delta) Syndrome. Subtypes are often written as APDS1 (PIK3CD mutations) and APDS2 (PIK3R1 mutations). An early name was PASLI disease, which stands for “p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency.” These names all point to the same problem: too much activity in the PI3K-delta signal inside white blood cells. This leads to weaker control of infections, swollen lymph nodes and spleen, and sometimes autoimmune disease or lymphomas. The PASLI label highlights a typical cell pattern: too few naïve T cells and too many “aged” or “senescent” T cells. NaturePMCJAC Online

---

Types

APDS1 (PIK3CD-related)
Caused by “gain-of-function” variants in PIK3CD (the gene for the p110δ catalytic subunit). The best-known hotspot is p.E1021K, but many other activating missense variants exist. These changes make the pathway over-signal even without the right outside triggers. PMC+1

APDS2 (PIK3R1-related)
Caused by disease-causing variants in PIK3R1 (the gene for the p85α regulatory subunit). Many are splice-site or truncating changes that weaken the normal “brake,” so signaling runs too high. The end result overlaps with APDS1: frequent infections, lymphoproliferation, and immune imbalance. NCBI

---

Causes

Note: The primary causes are genetic changes in PIK3CD or PIK3R1. The other items below describe how these changes act, common patterns, or factors that worsen disease activity. I list them in simple terms so the full picture is clear.

1. PIK3CD gain-of-function mutation (APDS1). A single altered DNA letter can make p110δ “over-active,” so lymphocytes stay switched on too easily and mature improperly. PMC+1

2. PIK3R1 loss-of-function or splice mutation (APDS2). Damaged p85α cannot restrain p110δ well, so the PI3K-delta signal runs high. NCBI

3. Hotspot variants (e.g., p.E1021K in PIK3CD). Some specific amino-acid changes are common and strongly activating. PMC

4. De novo mutation. The mutation appears new in the child (not found in parents), which explains cases without family history. NCBI

5. Autosomal dominant inheritance. One changed copy of the gene is enough to cause disease, so it can pass from an affected parent to a child. MedlinePlus

6. Mosaicism. In some people only a fraction of cells carry the mutation; disease can still occur but may vary in intensity. NCBI

7. Pathway hyper-signaling (PI3K→AKT→mTOR). The mutation heightens downstream signals (like pAKT and pS6), shifting cell survival and maturation. PMC+1

8. T-cell senescence. Over-signaling pushes T cells to an “aged” state (e.g., CD57+), reducing flexible responses to new germs. NaturePMC

9. Defective B-cell maturation. Transitional and naïve B-cell pools are abnormal; class-switching is often poor, so antibodies are weak or off-target. PMCJAC Online

10. EBV/CMV pressure on a weakly regulated immune system. Chronic herpesvirus activity flourishes when T- and B-cell regulation is off, worsening illness. JAC OnlineAll about APDS

11. Airway colonization from repeated infections. Each infection leaves damage that invites new infections (a “vicious cycle”). Immune Deficiency Foundation

12. Lymphoid tissue overgrowth (lymphoproliferation). Constant signaling causes swollen nodes/spleen and nodular lymphoid hyperplasia. MedlinePlus

13. Autoimmune mis-firing. Unbalanced signaling can lead the immune system to attack the body’s own blood cells or tissues. NCBI

14. Poor vaccine responses. Antibody quality can be weak, leaving gaps in protection even after shots. Immune Deficiency Foundation

15. Environmental irritants (e.g., smoke). Not a root cause, but can worsen airway infections and bronchiectasis in APDS. (General PID principle.) Immune Deficiency Foundation

16. Gut microbiome dysbiosis with immune dysregulation. Imbalanced signaling can favor nodular lymphoid hyperplasia and gut symptoms. MedlinePlus

17. Persistent inflammation in sinuses and ears. Ongoing swelling plus bacteria leads to chronic sinusitis and otitis media. Immune Deficiency Foundation

18. Secondary complications from repeated antibiotics/hospital care. These can select resistant germs and complicate infections in APDS. (General PID care pattern.) Immune Deficiency Foundation

19. Growth and development stressors. In children, constant illness strains nutrition and growth, revealing the disorder more clearly. MedlinePlus

20. Cancer predisposition (especially B-cell lymphomas). Long-term over-signaling and viral pressure can raise lymphoma risk. JAC OnlinePMC

---

Symptoms

1. Frequent ear infections. Repeats in childhood are common and may lead to hearing issues if untreated. Immune Deficiency Foundation

2. Chronic sinusitis. Stuffy nose, facial pain, and yellow-green drainage that keeps coming back. Immune Deficiency Foundation

3. Recurrent pneumonia. Cough, fever, chest pain, and breathlessness occur again and again. JAC Online

4. Bronchiectasis. Damaged airways that trap mucus and make infections more likely. JAC Online

5. Swollen lymph nodes. Painless lumps in the neck, armpits, or groin that persist. MedlinePlus

6. Enlarged spleen or liver. Fullness in the left or right upper belly and early satiety. MedlinePlus

7. Chronic viral infections (especially EBV/CMV). Fever, fatigue, and long-lasting “mono-like” illness. All about APDS

8. Gastrointestinal problems. Abdominal pain, diarrhea, or bowel nodules (nodular lymphoid hyperplasia). MedlinePlus

9. Skin infections and warts. Bacterial skin sores, molluscum, or persistent HPV warts. JAC Online

10. Mouth ulcers. Painful sores that repeat with stress or infections. JAC Online

11. Autoimmune cytopenias. Easy bruising, pale skin, or infections from low platelets, red cells, or neutrophils. NCBI

12. Fatigue and poor stamina. Ongoing tiredness from illness burden and inflammation. MedlinePlus

13. Allergy-like symptoms and wheeze. Some patients have asthma-type symptoms. JAC Online

14. Growth delay (children). Lost weight gain or short stature due to repeated illness and poor absorption. MedlinePlus

15. Lymphoma warning signs. Unexplained weight loss, night sweats, or long fevers in a patient with APDS need urgent review. PMC

---

Diagnostic tests

A) Physical exam (bedside observations)

1. Full lymph node exam. Checks size, number, and areas of swelling to judge lymphoproliferation or possible lymphoma. MedlinePlus

2. Abdominal palpation for spleen and liver. Looks for enlargement that fits APDS lymphoproliferation. MedlinePlus

3. ENT and chest exam. Ear drums, nasal passages, and lung sounds reveal chronic infections and airway damage. Immune Deficiency Foundation

4. Growth charting (children). Tracks height/weight to spot effects of repeated illness. MedlinePlus

5. Skin and oral mucosa check. Finds warts, molluscum, or mouth ulcers that signal immune imbalance. JAC Online

B) Manual / simple functional tests (clinic-level)

6. Peak expiratory flow or spirometry screening. Quick airway function check if wheeze or repeated pneumonias are present. JAC Online

7. 6-minute walk test. Simple measure of exercise tolerance when lungs are affected. (Generic but useful in chronic lung disease.) JAC Online

8. Manual lymph node measurement across visits. Tape or caliper tracking helps monitor size trends before imaging or biopsy. MedlinePlus

9. Stool occult blood/consistency logs. Practical tracking for gut involvement and malabsorption symptoms. MedlinePlus

C) Laboratory and pathological tests

10. Complete blood count (CBC) with differential. Looks for lymphopenia, anemia, thrombocytopenia, or neutropenia from infection or autoimmunity. MedlinePlus

11. Quantitative immunoglobulins (IgG, IgA, IgM). Finds low or imbalanced antibodies; IgM may be high in some, IgG/IgA low in others. Immune Deficiency Foundation

12. Specific antibody titers to vaccines. Tests if past vaccinations produced protective antibodies (often reduced). Immune Deficiency Foundation

13. Lymphocyte subsets by flow cytometry. Often shows fewer naïve T cells, increased senescent T cells, and abnormal B-cell compartments. JAC OnlinePMC

14. Functional lymphocyte assays (proliferation). Measures how T/B cells respond to stimulation; responses may be abnormal. NCBI

15. PI3K-pathway activity assay (e.g., pAKT, pS6). Ex vivo stimulation and intracellular flow cytometry document the over-active pathway. FDA Access DataResearchGate

16. Viral PCR loads (EBV, CMV, others). Checks for persistent or high-level herpesvirus activity that often complicates APDS. All about APDS

17. Genetic testing (PIK3CD, PIK3R1). Confirms the diagnosis and classifies APDS1 vs APDS2; may report known hotspots. NCBIPMC

18. Tissue biopsy when indicated (e.g., lymph node or gut). Pathology can separate reactive lymphoid overgrowth from lymphoma and confirm nodular lymphoid hyperplasia. JAC Online

D) Electrodiagnostic test

19. Electrocardiogram (ECG) when severe infection or treatment side effects raise concern. Not specific for APDS, but useful supportive monitoring in complex cases. (General clinical practice.)

E) Imaging tests

20. Chest CT and sinus CT (or MRI). Defines bronchiectasis, chronic sinus disease, and lymph node enlargement; guides further care. Ultrasound can measure spleen and liver size with no radiation. JAC Online

Non-pharmacological treatments

(15 physiotherapy; plus mind-body/gene-education therapies). Each includes description, purpose, mechanism, benefits. These support—not replace—medical care.)

Physiotherapy and respiratory care

1. Daily airway-clearance training (ACBT or OPEP device).
   Description: Learn a routine of breathing control, thoracic expansion, huffs, and device-assisted exhalation (e.g., oscillating PEP). Purpose: keep mucus moving. Mechanism: positive pressure and oscillations splint small airways, loosen secretions, improve collateral ventilation. Benefits: fewer flare-ups, better sputum clearance, quality of life. ThoraxPMC+1

2. Individualized airway-clearance plan with reviews.
   Description: A respiratory physiotherapist teaches a technique, then rechecks and adjusts. Purpose: maintain effective technique over time. Mechanism: tailoring frequency/duration (often 10–30 minutes) to symptoms. Benefits: safer, more effective self-management. British Thoracic Society

3. Nebulized isotonic/hypertonic saline when advised.
   Description: Sterile saline via nebulizer before clearance. Purpose: thin secretions. Mechanism: osmosis hydrates mucus; cilia beat better. Benefits: easier expectoration, less cough burden. British Thoracic Society

4. Postural drainage positions.
   Description: Specific body positions to drain segments. Purpose: gravity-assisted clearance. Mechanism: improves mucus flow from dependent bronchi. Benefits: complements ACBT/OPEP. PMC

5. Huff/forced-expiration technique.
   Description: Controlled open-glottis exhalations. Purpose: move mucus without airway collapse. Mechanism: shifts equal pressure point distally. Benefits: less tiring than cough; effective in bronchiectasis. CORE

6. Inhaler technique optimization.
   Description: Teach bronchodilator and inhaled therapy technique. Purpose: maximize delivery. Mechanism: correct inspiratory flow, timing, spacers. Benefits: better symptom control; fewer exacerbations. British Thoracic Society

7. Physical conditioning/aerobic exercise.
   Description: Walking, cycling, or swimming most days. Purpose: improve endurance and mucus mobilization. Mechanism: higher tidal volumes and ciliary motion. Benefits: fewer chest infections, quality-of-life gains. British Thoracic Society

8. Strength and posture training.
   Description: Core, shoulder-girdle work and posture drills. Purpose: open chest mechanics. Mechanism: increases thoracic expansion. Benefits: easier breathing, less fatigue. British Thoracic Society

9. Breathing pattern retraining.
   Description: Diaphragmatic, paced breathing. Purpose: reduce dyspnea/anxiety loop. Mechanism: lowers accessory muscle overuse. Benefits: more efficient ventilation. ERS Publications

10. Sputum-culture-guided flare plan.
    Description: Provide kits and instructions to submit sputum early. Purpose: faster targeted antibiotics. Mechanism: surveillance; early action. Benefits: less lung injury. Discovery

11. Annual physiotherapy review.
    Description: Formal check and update of regimen. Purpose: prevent technique drift. Mechanism: supervised optimization. Benefits: sustained benefits over years. British Thoracic Society

12. Nasal-sinus care (saline rinses, technique).
    Description: Routine nasal irrigation. Purpose: cut sinus bacterial load. Mechanism: mechanical clearance. Benefits: fewer sinus/ear infections feeding chest. Discovery

13. Airway-clearance intensification during colds.
    Description: Temporarily increase frequency/duration. Purpose: get ahead of secretions. Mechanism: matches mucus spikes. Benefits: prevent exacerbations. British Thoracic Society

14. Vaccination counseling (non-live).
    Description: Planning non-live vaccines and safe timing. Purpose: reduce preventable infections. Mechanism: passive and active immunity where appropriate. Benefits: fewer severe infections (e.g., influenza, pneumococcal). CDCThe Australian Immunisation Handbook

15. Environmental control & infection-prevention habits.
    Description: Hand hygiene, sick-contact avoidance, masks in high-risk settings, safe food/water. Purpose: lower exposure. Mechanism: barrier methods. Benefits: fewer infections overall. CDC

Mind-body, “gene-aware,” and educational therapies

16. Personalized APDS education.
    Description: Plain-language sessions on APDS biology, red flags, and meds. Purpose: confident self-management. Mechanism: informed decisions and adherence. Benefits: fewer delays, better outcomes. NCBI

17. Flare-action plan (written).
    Description: When to increase airway clearance, call the team, or start pre-agreed antibiotics. Purpose: rapid response. Mechanism: removes uncertainty. Benefits: shorter flares; reduced lung damage. British Thoracic Society

18. Vaccine-safety literacy for immunodeficiency.
    Description: Which vaccines are safe/effective; which live vaccines to avoid unless specialist says otherwise. Purpose: safe prevention. Mechanism: aligns with immunization best practices in altered immunocompetence. Benefits: protection without undue risk. CDCPubMed

19. Medication-adherence coaching.
    Description: Pill-box apps, routines, side-effect diaries. Purpose: keep levels steady (e.g., leniolisib, sirolimus). Mechanism: habit loops. Benefits: steadier control. PMC

20. Nutrition fundamentals (see food section).
    Description: Adequate protein, micronutrients, hydration. Purpose: support mucosa, immunity, and healing. Mechanism: supplies substrates for cells/antibodies. Benefits: better resilience. (General support; not disease-specific.)

21. Sleep and stress care.
    Description: Regular sleep, stress-reduction (breath work, CBT-I if needed). Purpose: modulate immune-neuroendocrine axis. Mechanism: lowers stress hormones that hinder defense. Benefits: fewer flares subjectively.

22. Psychological support.
    Description: Counseling for chronic-illness burden. Purpose: reduce anxiety/depression that impede adherence. Mechanism: coping skills. Benefits: better QoL.

23. School/work accommodations.
    Description: Absence flexibility during infections; ventilation and mask policies. Purpose: reduce exposure/load. Mechanism: environmental control. Benefits: fewer infections.

24. Family genetic counseling.
    Description: Explain autosomal-dominant inheritance, testing options for relatives. Purpose: earlier diagnosis in family. Mechanism: cascade screening. Benefits: proactive care. NCBI

25. Clinical trial awareness (no DIY “gene therapy”).
    Description: Discuss trials with your immunologist if available. Purpose: access to emerging options under supervision. Mechanism: monitored, ethical research—not home interventions. Benefits: possible added choices. (No approved gene therapy for APDS as of Sept 2025.)

---

Drug treatments

⚠️ Doses below are typical references, not personalized medical advice. Always follow your immunologist’s prescription and monitoring plan.

1. Leniolisib (JOENJA®) – PI3K-δ inhibitor; cornerstone targeted therapy.
   Class: selective PI3K-δ inhibitor. Typical dose/time: 70 mg orally twice daily (≥12 years, ≥45 kg). Purpose: shrink lymph nodes/spleen, improve immune balance, reduce infections/autoimmunity markers. Mechanism: turns down overactive PI3K-δ signaling. Side effects: headache, sinusitis, dermatitis acneiform, diarrhea; pregnancy precautions; monitor labs. FDA-labeled. FDA Access Data+1NCBI

2. Sirolimus (rapamycin) – pathway “downstream” modulator.
   Class: mTOR inhibitor. Dose: individualized to trough levels per specialist (often 5–15 ng/mL target). Purpose: reduce lymphoproliferation, help autoimmunity, sometimes infections. Mechanism: dampens mTOR overdrive downstream of PI3K. Side effects: mouth ulcers, high lipids, cytopenias, infection risk; drug interactions; requires monitoring. PMCFrontiers

3. Immunoglobulin replacement (IVIG/SCIG).
   Class: pooled human IgG. Dose: often ~0.4–0.6 g/kg/month (route and goal-trough individualized). Purpose: prevent bacterial/viral infections in antibody dysfunction. Mechanism: supplies functional antibodies. Side effects: infusion reactions, headache; rare thrombo-embolic or renal issues; adjust brand/route if needed. Wiley Online LibraryAAAAIImmune Deficiency Foundation

4. Antibiotic prophylaxis (e.g., trimethoprim-sulfamethoxazole per specialist plan).
   Class: antibacterial. Dose/time: low daily or intermittent prophylaxis when recurrent infections persist. Purpose: prevent ear/sinus/chest infections. Mechanism: suppress common airway pathogens. Side effects: rash, cytopenias; drug interactions—monitor.

5. Targeted, culture-guided antibiotics for exacerbations.
   Class: oral/IV antibiotics per sputum results. Dose/time: course length per guideline. Purpose: treat flares early to protect lungs. Mechanism: pathogen eradication. Side effects: GI upset, C. difficile risk; stewardship needed. Discovery

6. Rituximab (for autoimmune cytopenias/GLILD under specialist care).
   Class: anti-CD20 monoclonal antibody. Dose: regimens vary (e.g., 375 mg/m² weekly ×4 or 1,000 mg ×2 in some protocols). Purpose: control immune cytopenias or lymphoid lung disease. Mechanism: B-cell depletion resets autoimmunity. Side effects: infusion reactions, prolonged hypogammaglobulinemia (often needs Ig replacement), infection risk. NHS EnglandThe Open Rheumatology JournalPMC

7. Systemic corticosteroids (short courses only when needed).
   Class: glucocorticoid. Purpose: rescue for severe inflammation/autoimmunity. Mechanism: broad immunosuppression. Side effects: glucose rise, mood, bone effects; avoid chronic use when possible; taper carefully.

8. Mycophenolate mofetil (selected autoimmunity).
   Class: antiproliferative immunomodulator. Purpose: steroid-sparing for immune cytopenias/auto-inflammation. Mechanism: inhibits purine synthesis in lymphocytes. Side effects: cytopenias, GI, infections; pregnancy risks. PMC

9. Azathioprine (specialist-selected cases).
   Class: thiopurine immunomodulator. Purpose: steroid-sparing. Mechanism: DNA synthesis inhibition in immune cells. Side effects: marrow suppression (TPMT/NUDT15 testing), liver enzyme rise; infection risk.

10. Abatacept (case-by-case for immune dysregulation).
    Class: CTLA-4–Ig co-stimulation blocker. Purpose: calm T-cell overactivation in selected immune-dysregulation states. Mechanism: blocks CD28-mediated activation. Side effects: infections; infusion reactions. (Specialist decision; evidence evolving.)

11. Macrolide anti-inflammatories (e.g., azithromycin long-term in bronchiectasis).
    Class: antibiotic with immunomodulation. Purpose: reduce exacerbation frequency in bronchiectasis phenotype. Mechanism: decreases neutrophilic inflammation/biofilms. Side effects: QT prolongation, hearing issues; resistance risk; screen for NTM first per guidelines. British Thoracic Society

12. Antiviral therapy (e.g., for CMV/EBV complications when indicated).
    Class: antiviral agents. Purpose: treat significant viral reactivation/infection. Mechanism: virus-specific inhibition. Side effects: drug-specific (renal, marrow).

13. Antifungals (when cultures or imaging suggest fungal disease).
    Class: azoles/echinocandins. Purpose: treat invasive or allergic fungal disease (e.g., ABPA per guideline). Mechanism: fungal cell target inhibition. Side effects: liver enzymes, drug interactions. Discovery

14. Hematopoietic growth factors (see “regenerative” section; e.g., G-CSF).
    Class: cytokine. Purpose: support neutrophils in significant neutropenia. Mechanism: stimulates marrow production. Side effects: bone pain, spleen enlargement.

15. Pneumocystis prophylaxis (when immunosuppressed).
    Class: anti-Pneumocystis (often TMP-SMX). Purpose: prevent PCP in high-risk regimens. Mechanism: folate pathway inhibition. Side effects: as above; monitor.

---

Dietary “molecular” supplements

(General immune support; not APDS-specific cures. Discuss each with your clinician—some supplements interact with immunosuppressants.)

1. Vitamin D3 (e.g., 1,000–2,000 IU/day; individualized to serum level targets). Function: supports innate and adaptive immune regulation. Mechanism: vitamin D receptor signaling modulates cytokines and antimicrobial peptides. (Evidence supports deficiency correction for infection risk reduction in general populations; APDS-specific data are limited.)

2. Zinc (e.g., 10–20 mg elemental/day short-term). Function: lymphocyte function and barrier integrity. Mechanism: cofactor for enzymes and transcription factors; helps antiviral defenses. (Avoid long high doses → copper deficiency.)

3. Omega-3 (EPA/DHA) (e.g., 1 g/day). Function: anti-inflammatory lipid mediators. Mechanism: resolvins/protectins dampen airway inflammation; may complement bronchiectasis care.

4. Vitamin C (e.g., 200–500 mg/day). Function: antioxidant; neutrophil function. Mechanism: supports epithelial barrier and oxidative burst; benefits modest for common respiratory infections.

5. Probiotic strategy (specialist-guided). Function: gut barrier and immune crosstalk. Mechanism: microbiome modulation. Caution: rare bacteremia in immunodeficiency—use only if your clinician recommends a specific product.

6. Selenium (50–100 mcg/day). Function: antioxidant enzymes (glutathione peroxidases). Mechanism: supports redox balance and immune signaling.

7. N-acetylcysteine (NAC) (e.g., 600 mg once/twice daily if approved). Function: mucolytic/antioxidant. Mechanism: breaks disulfide bonds in mucus; replenishes glutathione. May aid airway symptoms in bronchiectasis.

8. Quercetin/Polyphenols (food-first approach). Function: antioxidant/anti-inflammatory effects. Mechanism: NF-κB modulation; limited clinical data—use as part of diet.

9. Curcumin (with piperine) (food-first). Function: anti-inflammatory signaling. Mechanism: multiple immune pathways; possible drug interactions—discuss first.

10. Protein-adequate nutrition (≈1.0–1.2 g/kg/day unless restricted). Function: antibody and tissue repair building blocks. Mechanism: supports immune cell synthesis.

---

Regenerative / stem-cell–related” medicines

(Used only under specialist care.)

1. Leniolisib – targeted pathway correction; see above. Function: re-balances immune signaling. Mechanism: selective PI3K-δ inhibition; may reduce lymphoid overgrowth and improve immunophenotype. FDA Access Data

2. Sirolimus – pathway modulation downstream of PI3K-δ; steroid-sparing for lymphoproliferation/autoimmunity. Mechanism: mTOR inhibition; therapeutic drug monitoring essential. PMC

3. G-CSF (filgrastim) – boosts neutrophils when significantly low. Mechanism: stimulates myeloid progenitors; dosing individualized; monitor spleen.

4. Eltrombopag – thrombopoietin-receptor agonist for immune thrombocytopenia refractory to first-line measures. Mechanism: stimulates megakaryocytes; monitor liver tests and interactions (chelation with polyvalent cations).

5. Romiplostim – injectable TPO-RA alternative for platelets; dosing titrated to response; monitor counts to avoid thrombosis.

6. Allogeneic hematopoietic stem-cell transplantation (HSCT) – definitive, potentially curative cellular therapy for selected severe APDS. Mechanism: replaces the immune system with donor stem cells. Benefits: long-term immune reconstitution. Risks: graft-versus-host disease, infections, conditioning toxicity. Reported survival ~80–86% in cohorts; undertaken only at expert centers after careful risk-benefit assessment. PMCScienceDirect

---

Surgeries / procedures

1. HSCT – see above; considered for severe, refractory disease or progressive organ damage. Why: potential cure via new immune system. PMC

2. Adenoidectomy/Tonsillectomy (selected cases). Procedure: remove hypertrophic lymphoid tissues causing airway obstruction or sleep-disordered breathing. Why: improve airflow, reduce infections/breathing pauses.

3. Tympanostomy (ear) tubes. Procedure: place tiny tubes to ventilate middle ear. Why: reduce recurrent otitis media and hearing loss-risk.

4. Endoscopic sinus surgery (refractory chronic sinusitis). Procedure: open drainage pathways. Why: decrease bacterial reservoir feeding lower airway infections.

5. Segmental lung resection or bronchoscopic clearance (rare, advanced bronchiectasis). Procedure: remove or clear localized, destroyed segments. Why: reduce recurrent sepsis when localized and unresponsive to conservative care.

---

Preventions

1. Up-to-date non-live vaccines (influenza, pneumococcal, COVID-19 per specialist). CDC

2. Avoid live vaccines unless an immunology specialist confirms safety. PubMed

3. Prompt airway-clearance daily; intensify during colds. British Thoracic Society

4. Sputum culture early in flares; take antibiotics exactly as prescribed. Discovery

5. Hand hygiene + masks in crowded/respiratory-season settings. CDC

6. Dental/sinus care to limit pathogen reservoirs.

7. Sleep, exercise, nutrition consistency.

8. Travel plan: vaccines/antibiotics/letters organized ahead.

9. Household education: what to do when someone is sick.

10. Regular specialist follow-up (immunology + respiratory).

---

When to see doctors

• Seek urgent care now for high fever with shaking chills; severe shortness of breath; chest pain; blood in sputum; confusion; rapid swelling of nodes/abdomen; bleeding/bruising; severe dehydration from diarrhea; or suspected sepsis.

• See your immunologist promptly for any new or frequent infections, persistent cough >3 weeks, weight loss, drenching night sweats, new autoimmune symptoms (easy bruising, pallor, jaundice), medication side effects (mouth ulcers, severe rash, persistent diarrhea), or steadily enlarging nodes/spleen despite therapy.

---

What to eat and what to avoid

1. Eat: protein at each meal (eggs, fish, legumes) to support antibodies/cilia.

2. Eat: colorful fruit/veg (polyphenols) for antioxidant defense.

3. Eat: omega-3 sources (fish, walnuts) for airway inflammation balance.

4. Eat: fermented foods only if your clinician approves; otherwise prefer pasteurized options in active immunosuppression.

5. Hydrate: warm fluids to keep mucus mobile.

6. Avoid: undercooked meats/eggs, unpasteurized dairy/juices during immunosuppression.

7. Avoid: smoking and secondhand smoke (cilia injury).

8. Limit: ultra-processed, high-sugar foods (pro-inflammatory).

9. Moderate: alcohol (drug interactions, immunity).

10. Time: space leniolisib and interacting agents as advised; avoid grapefruit with certain drugs (ask your pharmacist).

---

FAQs

1. Is APDS curable?
   Some people with severe disease can be effectively cured by HSCT; otherwise, targeted drugs like leniolisib, plus infection prevention and airway care, can control disease well. PMC

2. What’s the first targeted drug for APDS?
   Leniolisib—FDA-approved; usual dose 70 mg twice daily for eligible patients. FDA Access Data

3. Do I still need immunoglobulin if I’m on leniolisib?
   Many do, depending on infections and antibody function; your team decides using IgG levels and clinical history. Wiley Online Library

4. Are live vaccines safe?
   Generally avoid live vaccines unless your immunologist clears them; non-live vaccines are recommended. CDCPubMed

5. Why do I need airway-clearance if APDS is an immune problem?
   Because infections leave mucus and damage (bronchiectasis). Clearing mucus reduces bacteria and protects lungs. Thorax

6. Is sirolimus the same as leniolisib?
   No. Sirolimus blocks mTOR downstream; leniolisib blocks PI3K-δ upstream. Both can help; choice is individualized. PMC

7. Will rituximab make infections worse?
   It can lower B-cells for months; many patients need Ig replacement and careful monitoring afterward. NHS England

8. Could supplements replace my medicines?
   No. Supplements can support health but do not correct APDS signaling or replace antimicrobials/Ig/targeted therapy.

9. What’s the long-term outlook?
   With modern care—targeted therapy, airway management, and timely treatment—most people can avoid serious complications; severe cases may be considered for HSCT. PMC

10. Can family members be affected?
    APDS is usually autosomal dominant; first-degree relatives can be offered genetic counseling/testing. NCBI

11. Why do doctors keep sending sputum cultures?
    Because repeated cultures guide the right antibiotic and catch new organisms early—key in bronchiectasis. Discovery

12. Are there clinical trials?
    Occasionally yes; ask your immunologist to check current registries for APDS trials.

13. Can I exercise?
    Yes—gradually increase aerobic and strength training; it helps mucus clearance and stamina. British Thoracic Society

14. What about school/work?
    Reasonable accommodations (time off for infections, masks/ventilation) reduce risk and stress.

15. Who should coordinate my care?
    An immunologist working with respiratory, ENT, and infectious disease teams is ideal for comprehensive management.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 05, 2025.